PGHL
Procter & Gamble Health Limited
Vitamins, minerals and supplements under Procter & Gamble brands
Healthcare›Healthcare›Pharmaceuticals & Biotechnology›Pharmaceuticals
pghealthindia.com(opens the company website in a new tab)Key metrics
Price as of 2026-10-16
Stock price
₹5200.00
Market cap
8,632 Cr
Stock P/E
24.2
P/B
16.46
Dividend yield
3.9%
ROE (FY26)
62.3%
ROCE (FY26)
85.9%
Operating margin (FY26)
30.8%
Debt / equity (FY26)
0.00
OCF / EBITDA (FY26)
74.0%
Full years shown; sign in free for the trailing twelve months. Learn about these metrics →
Price & valuation
Share price and valuation multiples (P/E, P/B and more) over time.
Loading price history…
Compare with peers
Loading peers…
What you need to know
P&G Health (Procter & Gamble Health) makes and sells vitamins, minerals and supplements in India, through brands such as Neurobion, Livogen, Evion, Polybion, SevenSeas and Nasivion, to consumers and patients through chemists, e-pharmacies and other retail.
Company snapshot
46thBy market cap
Ranked among 119 companies in Pharmaceuticals.
What we see
Positives
- ✓Net margin of 23.2% — the business keeps a healthy share of every rupee it earns.
4 more signals from the filings.Sign in free to see them all
Statement tables · Standalone
Switches quarterly, P&L, balance sheet, and cash flow. Key metrics and ratios stay on consolidated when available.
Standalone only
Amounts in ₹ Cr · tap + to expand rows
Quarterly results
Quarterly · ₹ Cr · tap + rows to expand
| Metric | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 305 Cr | 310 Cr | 252 Cr | 284 Cr | 313 Cr | 310 Cr | 311 Cr | 339 Cr | 325 Cr | 374 Cr | 370 Cr | 364 Cr |
| Operating expenses (approx.) | 216 Cr | 208 Cr | 185 Cr | 236 Cr | 199 Cr | 186 Cr | 230 Cr | 248 Cr | 205 Cr | 263 Cr | 235 Cr | 264 Cr |
| EBITDA | 89 Cr | 102 Cr | 67 Cr | 48 Cr | 114 Cr | 123 Cr | 81 Cr | 90 Cr | 120 Cr | 110 Cr | 136 Cr | 100 Cr |
| OPM % | 29.1% | 32.8% | 26.7% | 17.0% | 36.4% | 39.8% | 26.0% | 26.7% | 37.0% | 29.5% | 36.6% | 27.4% |
| Other income | 6 Cr | 5 Cr | 2 Cr | 2 Cr | 3 Cr | 4 Cr | 3 Cr | 4 Cr | 5 Cr | 4 Cr | 4 Cr | 4 Cr |
| Interest | 0.18 Cr | 0.19 Cr | 0.15 Cr | 0.20 Cr | 0.15 Cr | 0.15 Cr | 0.13 Cr | 0.12 Cr | 0.12 Cr | 0.10 Cr | 0.21 Cr | 0.14 Cr |
| Depreciation | 6 Cr | 7 Cr | 7 Cr | 7 Cr | 6 Cr | 6 Cr | 5 Cr | 5 Cr | 6 Cr | 6 Cr | 6 Cr | 6 Cr |
| Profit before tax | 88 Cr | 100 Cr | 63 Cr | 23 Cr | 111 Cr | 122 Cr | 79 Cr | 89 Cr | 119 Cr | 109 Cr | 133 Cr | 129 Cr |
| Tax % | 25.5% | 27.7% | 25.8% | 26.5% | 26.1% | 25.3% | 22.1% | 25.5% | 25.6% | 28.7% | 29.0% | 25.5% |
| Net profit | 66 Cr | 72 Cr | 47 Cr | 17 Cr | 82 Cr | 91 Cr | 61 Cr | 66 Cr | 89 Cr | 78 Cr | 95 Cr | 96 Cr |
| EPS (₹) | ₹39.50 | ₹43.40 | ₹28.00 | ₹10.11 | ₹49.60 | ₹54.76 | ₹36.86 | ₹39.87 | ₹53.34 | ₹46.74 | ₹56.99 | ₹57.92 |
Profit & loss (annual)
Annual · last column is TTM · ₹ Cr · tap + to expand
| Metric | Dec 2017 | Dec 2018 | Dec 2019 | Jun 2020 | Jun 2021 | Jun 2022 | Jun 2023 | Jun 2024 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,119 Cr | 849 Cr | 927 Cr | — | 1,009 Cr | 1,114 Cr | 1,230 Cr | 1,151 Cr | 1,408 Cr | Sign in free for the trailing twelve months |
| Operating expenses (approx.) | 965 Cr | 702 Cr | 723 Cr | — | 763 Cr | 846 Cr | 906 Cr | 845 Cr | 951 Cr | Sign in free for the trailing twelve months |
| EBITDA | 155 Cr | 147 Cr | 204 Cr | — | 246 Cr | 268 Cr | 324 Cr | 306 Cr | 457 Cr | Sign in free for the trailing twelve months |
| OPM % | 13.8% | 17.4% | 22.0% | — | 24.4% | 24.1% | 26.3% | 26.6% | 32.4% | Sign in free for the trailing twelve months |
| Other income | 24 Cr | 24 Cr | 48 Cr | — | 18 Cr | 13 Cr | 18 Cr | 16 Cr | 17 Cr | Sign in free for the trailing twelve months |
| Interest | — | 0 Cr | 0 Cr | — | 0.80 Cr | 0.42 Cr | 0.77 Cr | 0.72 Cr | 0.55 Cr | Sign in free for the trailing twelve months |
| Depreciation | 26 Cr | 20 Cr | 17 Cr | — | 30 Cr | 28 Cr | 27 Cr | 27 Cr | 24 Cr | Sign in free for the trailing twelve months |
| Profit before tax | 152 Cr | 1,138 Cr | 234 Cr | — | 233 Cr | 253 Cr | 314 Cr | 273 Cr | 450 Cr | Sign in free for the trailing twelve months |
| Tax % | 38.3% | 26.3% | 32.3% | — | 24.2% | 24.0% | 27.0% | 26.5% | 27.3% | Sign in free for the trailing twelve months |
| Net profit | 94 Cr | 839 Cr | 159 Cr | — | 177 Cr | 193 Cr | 229 Cr | 201 Cr | 327 Cr | Sign in free for the trailing twelve months |
| EPS (₹) | ₹56.60 | ₹505.27 | ₹95.64 | — | ₹106.50 | ₹116.00 | ₹138.23 | ₹121.07 | ₹196.94 | Sign in free for the trailing twelve months |
| Dividend payout % | — | — | — | — | 215.9% | 147.4% | 40.9% | 206.5% | 104.1% | Sign in free for the trailing twelve months |
Sign in free for the trailing twelve months
The latest four quarters added up, next to each full year
Balance sheet
Annual · ₹ Cr · tap + rows to expand
| Metric | Dec 2017 | Dec 2018 | Dec 2019 | Jun 2020 | Jun 2021 | Jun 2022 | Jun 2023 | Jun 2024 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|
| Equity capital | 17 Cr | 17 Cr | 17 Cr | 17 Cr | 17 Cr | 17 Cr | 17 Cr | 17 Cr | 17 Cr |
| Reserves | 717 Cr | 1,524 Cr | — | 890 Cr | 687 Cr | 600 Cr | 734 Cr | 522 Cr | 508 Cr |
| Borrowings | — | — | — | — | — | — | — | — | — |
| Other liabilities | 258 Cr | 219 Cr | — | 269 Cr | 282 Cr | 277 Cr | 350 Cr | 256 Cr | 317 Cr |
| Total liabilities | 991 Cr | 1,759 Cr | — | 1,176 Cr | 986 Cr | 894 Cr | 1,101 Cr | 794 Cr | 841 Cr |
| Fixed assets (net) | 114 Cr | 99 Cr | — | 98 Cr | 101 Cr | 106 Cr | 130 Cr | 126 Cr | 99 Cr |
| CWIP | 9 Cr | 17 Cr | — | 21 Cr | 39 Cr | 41 Cr | 32 Cr | 6 Cr | 14 Cr |
| Investments | 70 Cr | 4 Cr | — | — | 3 Cr | 3 Cr | 2 Cr | 2 Cr | 3 Cr |
| Loans & advances | — | 0.06 Cr | — | — | 1 Cr | 2 Cr | 2 Cr | 2 Cr | 2 Cr |
| Inventories | 158 Cr | 113 Cr | — | 134 Cr | 118 Cr | 115 Cr | 135 Cr | 109 Cr | 137 Cr |
| Trade receivables | 123 Cr | 66 Cr | — | 95 Cr | 59 Cr | 83 Cr | 116 Cr | 85 Cr | 164 Cr |
| Cash & bank | 10 Cr | 1,120 Cr | — | 636 Cr | 464 Cr | 319 Cr | 435 Cr | 239 Cr | 177 Cr |
| Other assets | 507 Cr | 340 Cr | — | 192 Cr | 200 Cr | 225 Cr | 250 Cr | 226 Cr | 246 Cr |
| Total assets | 991 Cr | 1,759 Cr | — | 1,176 Cr | 986 Cr | 894 Cr | 1,101 Cr | 794 Cr | 841 Cr |
Cash flows
Annual · ₹ Cr · tap + rows to expand · last column includes FCF
| Metric | Dec 2017 | Dec 2018 | Dec 2019 | Jun 2020 | Jun 2021 | Jun 2022 | Jun 2023 | Jun 2024 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|
| Cash from operating activity | 54 Cr | -130 Cr | — | — | 247 Cr | 170 Cr | 236 Cr | 228 Cr | 338 Cr |
| Cash from investing | -48 Cr | 1,270 Cr | — | — | -32 Cr | -26 Cr | -21 Cr | -7 Cr | 1 Cr |
| Cash from financing | -22 Cr | -30 Cr | — | — | -387 Cr | -289 Cr | -98 Cr | -418 Cr | -344 Cr |
| Net cash flow | -16 Cr | 1,109 Cr | — | — | -172 Cr | -145 Cr | 116 Cr | -197 Cr | -5 Cr |
| Free cash flow (OCF − Capex) | 23 Cr | -157 Cr | — | — | 195 Cr | 132 Cr | 194 Cr | 207 Cr | 322 Cr |
Ratios
| Metric | Dec 2017 | Dec 2018 | Dec 2019 | Jun 2020 | Jun 2021 | Jun 2022 | Jun 2023 | Jun 2024 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|
| ROCE % | 20.8% | 73.9% | — | — | 33.3% | 41.2% | 41.9% | 50.9% | 85.9% |
| ROE % | 12.8% | 54.5% | 21.3% | — | 25.1% | 31.2% | 30.6% | 37.3% | 62.3% |
| Debtor days | 40 | 28 | — | — | 21 | 27 | 34 | 27 | 42 |
| Inventory days | 243 | 168 | — | — | 149 | 130 | 154 | 137 | 162 |
| Days payable | 128 | 136 | — | — | 162 | 198 | 270 | 210 | 228 |
| Cash conversion cycle | 154 | 61 | — | — | 8 | -41 | -82 | -46 | -23 |
| OCF / EBITDA % | 34.7% | -88.5% | — | — | 100.5% | 63.2% | 72.8% | 74.6% | 74.0% |
| OCF / EBITDA % (3 years) | — | — | — | — | — | — | 77.9% | 70.5% | — |
| Debt / equity | — | 0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Current ratio | 3.34 | 7.83 | — | 4.21 | 3.04 | 2.96 | 2.62 | 2.35 | 2.18 |
| Net debt / EBITDA | -0.07 | -7.60 | 0.00 | — | -1.89 | -1.19 | -1.34 | -0.78 | -0.39 |